Pharmaceuticals
Wugen Announces Exclusive Partnership Agreement With Alpha Biopharma in Asia For Cell Therapies to Treat Cancer
ST. LOUIS, March 8, 2021 /PRNewswire/ -- Wugen Inc., a clinical-stage biotechnology company developing novel universal natural killer (NK) and T-cell therapies for the treatment of cancer, today announced that it has entered into an exclusive license and collaboration agreement withShanghai-based...
2021-03-08 22:00
2969
Patients Win When Support Is Personalized: New Study From Atlantis Healthcare Shows Treatment Persistence and Adherence Improved by 38%
SYDNEY, March 8, 2021 /PRNewswire/ -- Leading patient outcomes journal Patient
Preference and Adherence
2021-03-08 08:48
1835
Cipla Gulf Expands Partnership with Alvotech for Commercialization of Biosimilars in Australia and New Zealand
MUMBAI, India, March 2, 2021 /PRNewswire/ -- Cipla Limited (BSE: 500087) (NSE: CIPLA EQ) referred to as "Cipla" today announced that its subsidiary, Cipla Gulf FZ LCC ("Cipla Gulf') is expanding its partnership with Alvotech for the marketing and distribution of four biosimilar medicines inAustra...
2021-03-02 22:05
5670
Merck and GPHL Collaborate on Business Innovation and Development in the Greater Bay Area
GUANGZHOU, China, March 2, 2021 /PRNewswire/ -- Merck, a leading science and technology company, today signed a Memorandum of Understanding (MOU) to begin strategic collaboration with Guangzhou Pharmaceutical Holdings Limited (GPHL), China's leading pharmaceutical company. The collaboration aim...
2021-03-02 18:12
3237
Oscotec and Beactica Therapeutics announce license and collaboration agreement to develop new cancer drug
STOCKHOLM, March 2, 2021 /PRNewswire/ -- Oscotec Inc. (039200: KOSDAQ), the Korean drug development company, and Beactica Therapeutics AB, the Swedish drug discovery company, today announced a new research development and licensing agreement. Oscotec and Beactica will initially jointly collaborat...
2021-03-02 15:21
1244
INOVIO Announces Positive Results from REVEAL 1, a Phase 3 Pivotal Trial Evaluating VGX-3100, its DNA-based HPV Immunotherapy for the Treatment of High-grade Precancerous Cervical Dysplasia Caused by HPV-16 and/or HPV-18
Trial achieved primary and secondary efficacy endpoints among all evaluable subjects in the Phase 3 multi-center, randomized, double-blind, placebo-controlled trial VGX-3100 is the first DNA medicine to achieve efficacy endpoints in a Phase 3 clinical trial INOVIO also continues to partner with...
2021-03-02 05:05
4748
Everest Medicines Announces Selection as a Constituent of Certain Indexes of Hang Seng Indexes Company Limited
SHANGHAI, March 1, 2021 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients inGreater China and other parts of Asia, today announced t...
2021-03-01 12:36
4097
Sciwind's Investigational New Drug Approved for NASH Trial
HANGZHOU, China, March 1, 2021 /PRNewswire/ -- Hangzhou Sciwind Biosciences Co., Ltd., (Sciwind), a clinical-stage, fast-growing biotech focusing on research and development of innovative biologics, today announced that XW003, a potential candidate for the treatment of non-alcoholic steatohepatit...
2021-03-01 09:00
2393
Innovent Announces First Patient Outside China Dosed in the Phase 1 Clinical Trial of Anti-CD47/PD-L1 Bispecific Antibody
SAN FRANCISCO and SUZHOU, China, March 1, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune and other major di...
2021-03-01 08:23
5771
Sirtex Medical receives positive recommendation from National Institute for Health and Care Excellence (NICE) for selective internal radiation therapy (SIRT) using SIR-Spheres®
NICE recommends SIR-Spheres® Y-90 microspheres as an option for treating unresectable advanced hepatocellular carcinoma (HCC) in adults WOBURN, Mass., Feb. 26, 2021 /PRNewswire/ -- Sirtex Medical US Holdings, Inc. ("Sirtex"), a leading manufacturer of targeted cancer therapies, received positive...
2021-02-26 23:37
2691
Debiopharm And Genome & Company Join Forces To Create New Highly Specific Therapies For Cancer Patients
Korean and Swiss based companies leverage their oncology expertise to initiate a research collaboration to formulate novel antibody-drug conjugate (ADC) candidates LAUSANNE, Switzerland and SEONGNAM-SI GYEONGGI-DO, South Korea, Feb. 26, 2021 /PRNewswire/ -- Genome & Company (CEO:Jisoo Pae, Hanso...
2021-02-26 19:14
3287
Harbour BioMed Announces NMPA Approval of IND for Combination Therapy of Next Gen Anti-CTLA-4 Antibody for Treatment of NSCLC and Solid Tumors
CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, Feb. 26, 2021 /PRNewswire/ -- Harbour BioMed (HBM) (HKEX: 02142) today announced that the China National Medical Products Administration (NMPA) has approved its Investigational New Drug (IND) application for HBM4003, the next generati...
2021-02-26 10:16
6603
New Data Presented at ACTRIMS Forum 2021 Indicate MAVENCLAD®-treated RMS Patients Mount Protective Antibody Response to Common Vaccines
DARMSTADT, Germany, Feb. 25, 2021 /PRNewswire/ -- Not intended for UK and U.S. based media Merck, a leading science and technology company, today announced the presentation of a new analysis from the MAGNIFY-MS study on MAVENCLAD® (cladribine tablets) in patients with relapsing multiple sclerosi...
2021-02-25 21:00
2619
Gannex Announces U.S. IND Approval and Initiation of Global Development of THR-β Agonist ASC41 for NASH
SHANGHAI, Feb. 24, 2021 /PRNewswire/ -- Gannex, a wholly owned company of Ascletis Pharma Inc. (HKEX: 1672), fully dedicated to the R&D and commercialization of new drugs in the field of nonalcoholic steatohepatitis (NASH), today announces the Investigational New Drug Application (IND) approval ...
2021-02-25 08:30
2797
WuXi Biologics Wins 2021 CMO Leadership Awards in All Six Core Categories
SHANGHAI, Feb. 25, 2021 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, today announced that the company has been named a winner of the 2021 CMO Leadership Awards for a fourth year in a row. The company is proud to ...
2021-02-25 08:00
1921
Insilico Medicine Achieves Industry First Nominating Preclinical Candidate Discovered by AI
Insilico Medicine Achieves Industry First Nominating Preclinical Candidate for Idiopathic Pulmonary Fibrosis With Both Novel Drug Target and Novel Molecule Discovered by Artificial Intelligence HONG KONG, Feb. 25, 2021 /PRNewswire/ -- Insilico Medicine has demonstrated a breakthrough in Artifici...
2021-02-25 00:48
2545
First cancer centers begin using initial release of Elekta's MOSAIQ 3 series
ATLANTA, Feb. 25, 2021 /PRNewswire/ -- Elekta (EKTA-B.ST) announced today that several cancer centers are the early adopters of the company's first release in the MOSAIQ® 3* series. Featuring increased automation and simplified user interfaces, MOSAIQ 3 is designed to significantly reduce workflo...
2021-02-25 00:46
4836
Occlutech announces Completion of Patient Enrolment in Pilot Study of Atrial Flow Regulator (AFR) in Patients with Heart Failure
SCHAFFHAUSEN, Switzerland, Feb. 24, 2021 /PRNewswire/ -- Occlutech, a privately-held company, announced today the completion of patient enrolment in its pilot study to assess safety and efficacy of the novel Atrial Flow Regulator (AFR) in heart failure (HF) patients (PRELIEVE trial). PRELIEVE is...
2021-02-24 20:41
2200
INOVIO and QIAGEN expand collaboration to develop next generation sequencing (NGS) companion diagnostic for INOVIO's VGX-3100 for advanced cervical dysplasia
- Liquid biopsy-based precision test guides patient selection and offers potential for cost-effective, non-invasive alternative to surgical removal of cervical lesions - QIAGEN's bioinformatic expertise raises predictive biomarker power in INOVIO's patient selection - First-in-class next genera...
2021-02-24 14:45
5910
Antengene Announces NDA for ATG-010 (Selinexor) Granted Priority Review by China's NMPA
SHANGHAI and HONG KONG, Feb. 24, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in class therapeutics in hematology and onco...
2021-02-24 08:00
2695
Week's Top Stories
Most Reposted
10 Start-ups Awarded in HK Tech 300 Southeast Asia Start-up Competition Fostering Innovation & Entrepreneurship Beyond Boundaries
[Picked up by 320 media titles]
2024-06-27 18:56
Labuan IBFC Inc. and STEP Malaysia jointly host wealth management and estate planning event
[Picked up by 318 media titles]
2024-06-28 12:45
Yidu Tech Announces Annual Results for FY 2024: Existing Business Achieves First Full-Year Profit on Adjusted EBITDA
[Picked up by 291 media titles]
2024-07-01 09:05
Fibocom Drives the Rapid Growth in the Economics of IoT Scale with Ultra-compact size Cat 1 bis Module MC610-GL at MWC Shanghai 2024
[Picked up by 286 media titles]
2024-06-26 10:00
Hukumonline Launches Comprehensive Law Firm Directory As a Guide for Investment and Business in Indonesia
[Picked up by 285 media titles]
2024-06-28 21:46
Most Read
Labuan IBFC Inc. and STEP Malaysia jointly host wealth management and estate planning event
2024-06-28 12:45
11718
iQIYI Unveils Over 250 New Shows at 4th Annual Content Showcase in North America
2024-06-28 19:00
8472
